Skip to main content
Premium Trial:

Request an Annual Quote

Life Technologies, Bioheart Team on Stem Cell Research Offering

NEW YORK (GenomeWeb News) – Bioheart, a Sunrise, Fla.-based developer of stem cell therapies for cardiovascular diseases, today said that it has entered into a global distribution and OEM pact for Life Technologies to sell the firm’s myoblast cell-based research products to life science researchers.
Bioheart said that the myoblast products will complement Life Technologies’ current portfolio of reagents for isolating, characterizing, expanding, and differentiating stem cells.
“This distribution agreement will give us access to the research community and will expand the number of therapeutic applications under development with this type of cell,” Bioheart Chairman, CEO, and CTO Howard Leonhardt said in a statement.
Financial terms of the agreement were not disclosed.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.